GoAI
Get started
Dianthus Therapeutics, Inc. logo

Dianthus Therapeutics, Inc.

DNTH

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$111.1

+$1.59 · +1.45%

Aug 21, 4:00 PM ET

DNTH company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

32

Expensive

Momentum

70

Gaining

Sentiment

58

Mixed

Risk resilience

65

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Marino Garcia
Listed since
Jun 21, 2018
Employees
92

Market position

Day range

Current $111.1

52-week range

Current $111.1

Open
$110.44
Previous close
$109.51
Volume
730.87K
0.82× average
Average volume
889.69K
Average daily volume
Market cap
6.21B USD
Beta
0.08
Market reference 1
50-day average
$100.38
+10.68% above average
200-day average
$72.4074
+53.44% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.51B USD
P/E (TTM)
-854.62×
P/B (TTM)
5.31×
P/S (TTM)
3,263.82×
EV / EBITDA
-9.31×
Earnings yield
-10.42%
Free cash flow yield
-8.30%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
96.01%
Operating margin
-11441.39%
Net margin
-1570.85%
Return on equity
-32.90%
Return on assets
-30.58%
Return on invested capital
-35.55%

Financial health

Debt / equity
0×
Current ratio
13.32×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends984%-2552%-6088%-9623%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2024: 100.00%Gross margin, FY2025: 100.00%Operating margin, FY2021: -886.59%Operating margin, FY2022: -462.91%Operating margin, FY2023: -1704.67%Operating margin, FY2024: -1633.74%Operating margin, FY2025: -8739.34%Net margin, FY2021: -888.14%Net margin, FY2022: -443.76%Net margin, FY2023: -1541.22%Net margin, FY2024: -1362.77%Net margin, FY2025: -7973.33%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2024 100.00%. Gross margin FY2025 100.00%. Operating margin FY2021 -886.59%. Operating margin FY2022 -462.91%. Operating margin FY2023 -1704.67%. Operating margin FY2024 -1633.74%. Operating margin FY2025 -8739.34%. Net margin FY2021 -888.14%. Net margin FY2022 -443.76%. Net margin FY2023 -1541.22%. Net margin FY2024 -1362.77%. Net margin FY2025 -7973.33%.

Income trends

Revenue

2.04M USD-67.35%

Operating income

−177.93M USD-74.68%

Net income

−162.34M USD-91.05%
Income trends across reported periods24.85M USD−48.89M USD−122.63M USD−196.37M USDRevenue, FY2021: 1.48M USDRevenue, FY2022: 6.42M USDRevenue, FY2023: 2.83M USDRevenue, FY2024: 6.24M USDRevenue, FY2025: 2.04M USDOperating income, FY2021: −13.09M USDOperating income, FY2022: −29.71M USDOperating income, FY2023: −48.17M USDOperating income, FY2024: −101.86M USDOperating income, FY2025: −177.93M USDNet income, FY2021: −13.11M USDNet income, FY2022: −28.48M USDNet income, FY2023: −43.56M USDNet income, FY2024: −84.97M USDNet income, FY2025: −162.34M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.48M USD. Revenue FY2022 6.42M USD. Revenue FY2023 2.83M USD. Revenue FY2024 6.24M USD. Revenue FY2025 2.04M USD. Operating income FY2021 −13.09M USD. Operating income FY2022 −29.71M USD. Operating income FY2023 −48.17M USD. Operating income FY2024 −101.86M USD. Operating income FY2025 −177.93M USD. Net income FY2021 −13.11M USD. Net income FY2022 −28.48M USD. Net income FY2023 −43.56M USD. Net income FY2024 −84.97M USD. Net income FY2025 −162.34M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue2.04M USD6.24M USD2.83M USD6.42M USD1.48M USD
Gross profit2.04M USD6.24M USD2.83M USD6.42M USD1.48M USD
Research and development145.64M USD83.11M USD32.84M USD29.38M USD12.61M USD
Selling, general, and administrative34.33M USD24.99M USD18.16M USD6.74M USD1.96M USD
Operating expenses179.97M USD108.1M USD51M USD36.12M USD14.56M USD
Interest income16.12M USD17.37M USD4.76M USD1.15M USD100K USD
Depreciation and amortization428K USD412K USD355K USD147K USD2.02M USD
Operating income−177.93M USD−101.86M USD−48.17M USD−29.71M USD−13.09M USD
Net income−162.34M USD−84.97M USD−43.56M USD−28.48M USD−13.11M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
45%
5 beats, 6 misses, 0 met estimates
Average EPS surprise
-3.56%
11 comparable reports
Latest EPS result
-0.9
Estimate -0.85 · Miss by 6.35%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.75-1-1.24-1.49Q1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 11, 2025: actual -0.81, estimate -0.85, surprise +4.71%, Beat. Q2 2025, reported May 12, 2025: actual -0.82, estimate -0.86, surprise +4.65%, Beat. Q3 2025, reported Aug 7, 2025: actual -0.88, estimate -0.86, surprise -2.33%, Miss. Q4 2025, reported Nov 5, 2025: actual -0.97, estimate -0.86, surprise -12.79%, Miss. Q1 2026, reported Mar 9, 2026: actual -1.43, estimate -0.98, surprise -45.92%, Miss. Q2 2026, reported May 5, 2026: actual -0.85, estimate -1.17, surprise +27.35%, Beat. Q3 2026, reported Aug 4, 2026: actual -0.9, estimate -0.846, surprise -6.35%, Miss. Q4 2026, reported Nov 4, 2026: actual —, estimate -1.02, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates1.42M998.39K581.22K164.05KQ1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 11, 2025: actual 1.33M USD, estimate 955.22K USD, surprise +38.71%, Beat. Q2 2025, reported May 12, 2025: actual 1.16M USD, estimate 806.9K USD, surprise +44.13%, Beat. Q3 2025, reported Aug 7, 2025: actual 193K USD, estimate 858.2K USD, surprise -77.51%, Miss. Q4 2025, reported Nov 5, 2025: actual 396K USD, estimate 576K USD, surprise -31.25%, Miss. Q1 2026, reported Mar 9, 2026: actual 284K USD, estimate 552.23K USD, surprise -48.57%, Miss. Q2 2026, reported May 5, 2026: actual 463K USD, estimate 403.62K USD, surprise +14.71%, Beat. Q3 2026, reported Aug 4, 2026: actual 761K USD, estimate 297.18K USD, surprise +156.07%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 400.83K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

11 ratings
Strong buy19%
Buy1091%
Hold00%
Sell00%
Strong sell00%

DNTH news

globenewswire.com

Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors

Antwerp, Belgium, August 10, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab" or the "Company"), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that its Board of…

Read source
defenseworld.net

California State Teachers Retirement System Raises Stock Holdings in Dianthus Therapeutics, Inc. $DNTH

California State Teachers Retirement System boosted its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ: DNTH) by 155.5% in the undefined quarter, according to the company in its most recent Form 13F filing with…

Read source
defenseworld.net

Dimensional Fund Advisors LP Purchases 114,767 Shares of Dianthus Therapeutics, Inc. $DNTH

Dimensional Fund Advisors LP lifted its position in Dianthus Therapeutics, Inc. (NASDAQ: DNTH) by 54.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The…

Read source
zacks.com

Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates

Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Estimate of a loss of $0.93. This compares to a loss of $0.88 per share a year ago.

Read source
globenewswire.com

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results

Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic Inflammatory…

Read source
globenewswire.com

Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases

DNTH312 is an internally developed bifunctional fusion protein targeting potent inhibition of active C1s (aC1s) and BAFF/APRIL, two validated pathways with complementary disease modifying mechanisms DNTH312 demonstrated…

Read source

DNTH peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding DNTH

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
177.02M
Weight
0.01%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
149.51M
Weight
1.31%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
131.92M
Weight
0.16%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
49.12M
Weight
0.05%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
48.34M
Weight
0.32%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
28.39M
Weight
0.16%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
20.95M
Weight
0.09%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%
T. Rowe Price Capital Appreciation Equity ETF logoT. Rowe Price Capital Appreciation Equity ETFTCAF
Market value
16.3M
Weight
0.20%
AUM
8.27B USD
Expense ratio
0.31%
Price / 1D
$42.46+0.35%

Continue in GoAI

Research DNTH

research.disclaimer